Edison Investment Research publishes an updated research note of Cereno Scientific and an executive CEO interview with Sten R. Sörensen
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announces that the equity research company Edison Investment Research has published an updated research note of the company and an executive interview with CEO Sten R. Sörensen highlighting the Q3 report.In the interview, Cereno's CEO Sten R. Sörensen comments on the recently released Q3 report, the company's strategy for rare diseases, how the recently completed capital raise of 250 million kronor will be